New Launch23 Aug 2024, 07:40 pm
Sun Pharma Launches Novel Treatment STARIZO in India for ABSSSI
AI Summary
Sun Pharmaceutical Industries Ltd. has launched Tedizolid Phosphate tablets 200 mg in India under the brand name ‘STARIZO’ for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The drug is effective against drug-resistant bacteria such as MRSA and offers the convenience of once-a-day dosing for six days. The treatment is particularly beneficial for patients with associated comorbidities such as diabetes, obesity, renal and hepatic dysfunction.
Key Highlights
- Sun Pharma launches STARIZO (Tedizolid Phosphate) in India for ABSSSI treatment
- STARIZO is effective against drug-resistant bacteria such as MRSA
- The treatment offers the convenience of once-a-day dosing for six days
- STARIZO has demonstrated activity against gram-positive organisms, including MRSA
- No dose adjustment is required in the elderly, patients with hepatic or renal impairment, and patients on haemodialysis